RecruitingNot ApplicableNCT03223922
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
Preservation of Cognition and Neuropsychiatric Functioning With Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases: A Pilot Study
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Enrollment
24 participants
Start Date
Jul 19, 2017
Study Type
INTERVENTIONAL
Conditions
Summary
This is a trial that evaluates the preservation of cognition and neuropsychiatric function following genu-sparing whole brain radiation in patients with brain metastases.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria11
- Histologic proof or unequivocal cytologic proof solid tumor malignancy. This may be obtained from either the primary or any metastatic site
- Mini Mental State Examination (MMSE) ≥24
- Age≥ 18 years
- Karnofsky Performance Status (KPS) ≥70
- Patient does not have metastases to the genu
- Patient must be scheduled to undergo treatment with whole brain radiation therapy (WBRT) to manage the brain metastases
- Patients of childbearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation therapy on an unborn child
- Patient must have the ability to understand and the willingness to sign a written informed consent document
- All patients must be informed of the investigational nature of this study and must be given written informed consent in accordance with institutional and federal guidelines
- Patient must have a minimal life expectancy of at least 6 months
- Patients receiving prior stereostatic radiosurgery (SRS) for brain metastases are eligible
Exclusion Criteria7
- Prior WBRT
- MMSE\<24
- Patient has brain metastases in the genu
- Patients must not have a serious medical or psychiatric illness that would, in the opinion of the treating physician prevent informed consent or completion of protocol treatment, and/or follow-up visits.
- KPS\<70
- Non-native English speakers will be excluded since patients often lose their faculty with the language they acquired second before their native language is affected in the context of cognitive decline. This could adversely affect performance on verbal cognitive tasks.
- Patients with absolute contraindication to MRI imaging are not eligible for the study
Interventions
RADIATIONwhole brain radiation therapy
Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03223922
Related Trials
Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers
NCT074644701 location
The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?
NCT053786331 location
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
NCT059876443 locations
Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)
NCT070530331 location
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
NCT055598531 location